UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 23, 2010

NUTRA BIOPHARMA CORP.
(Name of small business issuer specified in its charter)

Nevada	000-53657	30-0496950
(State or other jurisdiction	(Commission File No.)	(I.R.S. Employer
of incorporation)		Identification No.)

9 Via Del Garda
Henderson, NV 89011
(Address of principal executive offices)

(310) 733-8079
(Registrant’s telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Information.

On June 23, 2010, the Company’s Board of Directors adopted a Code of Ethics, a copy of which is attached hereto as Exhibit 14.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:

Exhibit 14: Code of Ethics

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NUTRA BIOPHARMA CORP.

Date: June 23, 2010	By:	/s/ Zirk Engeblrecht
		Zirk Engelbrecht
		Chief Financial Officer, Director

Nutra Biopharma Corp. 8-K